Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of physiology and biochemistry

• Publication date

  2010-07-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13105-010-0022-xPMID 20596903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multiple matrix metalloproteinases in type II collagen induced arthritis

  2009cited by this paper
• Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus.

  2008cited by this paper
• Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects

  2008cited by this paper
• Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis.

  2007cited by this paper
• Effective Therapy with Anti‐TNF‐α in Patients with Psoriatic Arthritis Is Associated with Decreased Levels of Metalloproteinases and Angiogenic Cytokines in the Sera and Skin Lesions

  2007cited by this paper
• IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors

  2007cited by this paper
• Tumor necrosis factor alpha −308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China

  2007cited by this paper
• Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis

  2007cited by this paper
• Decursin Inhibits Induction of Inflammatory Mediators by Blocking Nuclear Factor-κB Activation in Macrophages

  2006cited by this paper
• Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis.

  2006cited by this paper
• NF-κBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1β-induced and TNF-α-induced chondrocytes

  2006cited by this paper
• Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis.

  2006cited by this paper
• NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes.

  2006cited by this paper
• Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography

  2005cited by this paper
• Tumor necrosis factor-alpha -308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans.

  2005cited by this paper
• International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.

  2004cited by this paper
• MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis

  2004cited by this paper
• Tumour necrosis factor α G→A −238 and G→A −308 polymorphisms in juvenile idiopathic arthritis

  2002cited by this paper
• Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.

  2002cited by this paper
• Tumour necrosis factor alpha G-->A -238 and G-->A -308 polymorphisms in juvenile idiopathic arthritis.

  2002cited by this paper
• Tumor necrosis factor promoter polymorphisms in patients with rheumatoid arthritis in Taiwan.

  2001cited by this paper
• Cytokine pathways and joint inflammation in rheumatoid arthritis.

  2001cited by this paper
• TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus.

  2000cited by this paper
• Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis.

  2000cited by this paper
• Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes.

  1999cited by this paper
• Polymorphism of the human TNF-alpha promoter--random variation or functional diversity?

  1999cited by this paper
• Long-Term Follow-Up of Cytokines and Soluble Cytokine Receptors in Peripheral Blood of Patients with Juvenile Rheumatoid Arthritis

  1999cited by this paper
• Polymorphism of the human TNF-α promoter — random variation or functional diversity?

  1999cited by this paper
• Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′‐flanking region of the TNFα gene and HLA genes

  1999cited by this paper
• Tumour necrosis factor (TNF) gene polymorphism influences TNF‐α production in lipopolysaccharide (LPS)‐stimulated whole blood cell culture in healthy humans

  1998cited by this paper
• Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis.

  1997cited by this paper
• Preliminary definition of improvement in juvenile arthritis.

  1997cited by this paper
• Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

  1997cited by this paper
• Secretion of Tumour Necrosis Factor α and Lymphotoxin α in Relation to Polymorphisms in the TNF Genes and HLA‐DR Alleles. Relevance for Inflammatory Bowel Disease

  1996cited by this paper
• Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis.

  1996cited by this paper
• Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker.

  1996cited by this paper
• Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease.

  1996cited by this paper
• Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus.

  1995cited by this paper

• TNF-induced metalloproteinase-9 production is associated with neurological manifestations in HTLV-1-infected individuals

  2022cites this paper
• Genetic Variants and Therapeutic Response to Anti–TNF-α Agents in Juvenile Idiopathic Arthritis

  2022cites this paper
• Current insights in the pathogenesis of scleritis.

  2020cites this paper
• The association of CAT-262C/T polymorphism with catalase activity and treatment response in juvenile idiopathic arthritis

  2019cites this paper
• The protease systems and their pathogenic role in juvenile idiopathic arthritis.

  2019cites this paper
• Association between interleukin-1, interleukin-6, and tumor necrosis factor-alpha polymorphisms and juvenile idiopathic arthritis: a meta-analysis.

  2019cites this paper
• The role of the immune response mediator genes polymorphism in the predisposition to juvenile idiopathic arthritis

  2019cites this paper
• Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis

  2018cites this paper
• Neutrophil activation signature in juvenile idiopathic arthritis indicates the presence of low-density granulocytes

  2018cites this paper
• The immune response mediator genes polymorphic variants as predictors of the etanercept efficacy in juvenile idiopathic arthritis

  2018cites this paper
• The association between TNF-α 238A/G and 308A/G polymorphisms and juvenile idiopathic arthritis

  2018cites this paper
• Association of tumor necrosis factor–α (G-308A) genetic variant with matrix metalloproteinase–9 activity and joint destruction in early rheumatoid arthritis

  2017cites this paper
• TNF-α gene polymorphisms and juvenile idiopathic arthritis: Influence on disease outcome and therapeutic response.

  2015cites this paper
• [Tumor necrosis factor alpha (TNF-α) in autoimmune diseases (AIDs): molecular biology and genetics].

  2014cites this paper
• Pharmakogenetik bei juveniler idiopathischer Arthritis

  2014cites this paper
• El factor de necrosis tumoral α (TNF-α) en las enfermedades autoinmunes (EA): biología molecular y genética

  2014cites this paper
• Best Practice & Research Clinical Rheumatology

  2014cites this paper
• Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?

  2014cites this paper
• Therapeutic advancements in juvenile idiopathic arthritis.

  2014cites this paper
• Update on Genetic Susceptibility and Pathogenesis in Juvenile Idiopathic Arthritis

  2014cites this paper
• Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy.

  2013cites this paper
• The role of TNF-α and TNF-β gene polymorphism in the pathogenesis of Rheumatoid Arthritis

  2013cites this paper
• Etanercept attenuates short-term cigarette-smoke-exposure-induced pulmonary arterial remodelling in rats by suppressing the activation of TNF-a/NF-kB signal and the activities of MMP-2 and MMP-9.

  2012cites this paper
• TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?

  2012cites this paper